All Companies

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Pioneering a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Private 2007 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Private 2008 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. Private 2007 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Using T2MR to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare. Private 2006 View Profile
<a href="/venture-capital/all-companies/bizo">Bizo</a> Private 2008 View Profile
<a href="/venture-capital/all-companies/transmedics-inc">TransMedics, Inc.</a> Extending the life saving benefits of organ transplantation to patients suffering from end-stage organ failure. Private 2010 View Profile
<a href="/venture-capital/all-companies/alvine-pharmaceuticals-inc">Alvine Pharmaceuticals, Inc.</a> Developing biologics to target autoimmune/inflammatory diseases. Private 2006 View Profile
<a href="/venture-capital/all-companies/avedro-inc">Avedro, Inc.</a> Advancing the science and technology of corneal crosslinking and refractive correction. Private 2009 View Profile
<a href="/venture-capital/all-companies/black-duck-software-inc">Black Duck Software, Inc.</a> Providing the world’s only end-to-end platform for OSS Logistics. Private 2004 View Profile
<a href="/venture-capital/all-companies/quantum-designs">Quantum Designs</a> Commercializing breakthrough, innovative products in human nutrition. Private 2012 View Profile
<a href="/venture-capital/all-companies/brainshark-inc">Brainshark, Inc.</a> Delivers solutions for rich-media communication. Private 1999 View Profile
<a href="/venture-capital/all-companies/carbon-design-systems">Carbon Design Systems</a> Developing electronic design automation tool for high-performance virtual system prototypes Private 2002 View Profile
<a href="/venture-capital/all-companies/celexion-llc">Celexion LLC</a> Developing powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. Private 2009 View Profile
<a href="/venture-capital/all-companies/permeon-biologics-inc">Permeon Biologics Inc.</a> Pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Private 2011 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing a pipeline of innovative treatments for bladder diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals. Private 2007 View Profile
<a href="/venture-capital/all-companies/oasys-water-inc">Oasys Water, Inc.</a> Leading the world in the development of forward osmosis based solutions for the treatment and desalination of high saline source waters. Private 2009 View Profile
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Provider of leading technology for the conversion of biomass to fuels and chemicals. Private 2006 View Profile
<a href="/venture-capital/all-companies/pervasis-therapeutics-inc">Pervasis Therapeutics, Inc.</a> Developing novel therapeutics to promote vascular repair. Private 2003 View Profile